PATENT CLAIM ANALYSIS

Application Number: 15990095
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "183000"]

Abstract:
Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.

Claim (Index 35):
The conjugate of  claim 31 , wherein the tripeptide comprises an optionally substituted phenylalanine and a substituted tyrosine.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 93.0
- Lexical Diversity: 1.55556
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15990144', '15990111', '15990083', '15990136', '15606913']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8110800863730964
- 35 USC 102 Novelty (BERT): 0.6054362774191824
- Combined Prediction Score: 0.790515705477705
- Mean Citation Score: 630.275268
- Max Citation Score: 637.82324
- Similarity Product: 424.18307215446

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test